Research programme: RNA interference-based therapeutics - Generex/RXi

Drug Profile

Research programme: RNA interference-based therapeutics - Generex/RXi

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator Generex Biotechnology Corporation; RXi Pharmaceuticals Corporation
  • Developer Generex Biotechnology Corporation; RXi Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Gene silencing; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 30 May 2014 No development reported for Haematological malignancies in USA (Parenteral)
  • 06 Jan 2011 Early research in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top